Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease.
Today, Australian drug developer NeuClone announced positive preclinical results of its proposed ustekinumab biosimilar referencing Stelara. Ustekinumab is a monoclonal antibody that targets interleukin-12 and -23, and the reference product is approved to treat plaque psoriasis, psoriatic arthritis, and Crohn disease (CD).
The company announced that it had confirmed the similarity of its molecule to that of the reference product using an X-ray crystallography analysis of both primary amino acid sequence and 3-dimensional folding structure.
NeuClone is developing the proposed product with its partner, Serum Institute of India, and is scaling up to support a planned phase 1 trial of the biosimilar in 2019. Other biosimilars in the drug developer’s pipeline include trastuzumab (referencing Herceptin), which is slated to enter a phase 1 trial in 2018, and preclinical candidates for denosumab (referencing Prolia), palivizumab (referencing Synagis), and adalimumab (referencing Humira), and an additional 5 undisclosed products.
While the market for psoriasis treatments is heating up, with biologic competitors such as guselkumab (Tremfya) and ixekizumab (Taltz) vying for market share, Stelara’s most recently approved indication for the treatment of CD—which the FDA granted in September 2016 on the basis of positive data from 3 pivotal phase 3 studies—helps to buoy sales of the drug for Johnson & Johnson. In the treatment landscape for CD, the option to use an interleukin blocker provides an important alternative for patients who have not had an adequate response to treatment with an anti—tumor necrosis factor therapy.
On the strength of Stelara’s sales in all 3 indications, in its third-quarter 2017 earnings update, Johnson & Johnson, maker of the reference Stelara, reported $800 million in US sales for the quarter, up 42% from the same period in 2016, and $324 million in international sales, up 28.1%.
Another company that has disclosed its efforts to develop a biosimilar of the ustekinumab molecule is German drug maker Formycon, which, together with its partner Aristo Pharma, is in preclinical development with its candidate, FYB202.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.